INTRODUCTION {#s1}
============

Liver cancer is the fifth most common cancer worldwide and the second most frequent cause of cancer mortality with over 748,300 new cases every year, half of which are in China[@b1],[@b2]. Hepatocellular carcinoma (HCC) is the most common type of liver cancer[@b3]. Although surgical resection and liver transplantation are regarded as the best treatment for a curative prognosis of early-stage HCC[@b4], about 85% patients are not suitable for surgery due to locally advanced tumor or distant metastasis[@b5]. Discovery and application of biomarkers that incorporate with traditional cancer staging improve patient care. Thus, substantial efforts have been made to identify biomarkers as prognostic factors for improving therapeutic effect and prognosis prediction.

Pseudogenes are structurally similar to genes that encode functional proteins, but unable to encode fully functional proteins in most cases. Thus, pseudogenes have long been considered as nonfunctional sequences of genomic DNA. However, emerging evidence suggests that pseudogenes may harbor the potential to regulate the expression of their ancestral protein-coding genes by serving as a source of small interfering RNAs (siRNAs), antisense transcripts, microRNA (miRNA) binding sites, or competing mRNAs[@b6]-[@b8]. Furthermore, pseudogenes regulate tumor suppressors and oncogenes by acting as microRNA decoys[@b9]-[@b14]. To date, several studies have reported the association between pseudogene expression and multiple cancer risk. Ishiguro et al. reported that two pseudogenes (*NANOG1* and *NANOGP8*) were differentially expressed in colon cancer cells, and their expression might contribute to the proliferation of colon cancer cells[@b15]. Similar results were found for the association of *POU5F1P1* expression with prostatic carcinoma[@b16], *PTENP1* expression with melanoma[@b17], and *NANOGP8* expression with gastric cancer[@b18]. However, little is known about pseudogenes and cancer prognosis.

Functional polymorphisms in pseudogenes, such as single nucleotide polymorphisms (SNPs) influencing miRNAs binding, may affect the expression or function of the proteins[@b19],[@b20]. Thus, we speculate that potentially functional polymorphisms in pseudogenes may affect the expression of pseudogenes or its original protein-coding genes by influencing miRNA binding affinity, and thus play a role in the development and progression of human cancer. In this study, we examined the associations between six genetic variants of pseudogenes and prognosis of 331 patients with intermediate or advanced HCC in Chinese.

SUBJECTS AND METHODS {#s2}
====================

Subjects {#s2a}
--------

The protocol was approved by the local institutional review board at the authors\' affiliated institution. Written informed consent was obtained from every subject. The enrollments of subjects were described previously[@b21],[@b22]. For constructing a relatively homogenous population, our current study was restricted to HCC patients without surgery in intermediate stage (B) or advanced stage (C) according to the Barcelona Clinic Liver Cancer (BCLC) staging system[@b23],[@b24]. We recruited 414 intermediate or advanced HCC patients from Nantong Tumor Hospital and the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. All patients were followed up prospectively every three months from the time of enrollment by personal or family contacts until death or last time of follow-up. As a result, a total of 331 intermediate or advanced HCC patients who had completed follow-ups and clinical information were enrolled in our study with a response rate of 80.0%. The maximum follow-up time (MFT) for the 331 patients involved in the present study was 60.7 months (last follow-up in January 2013) and the median survival time (MST) was 14.5 months.

Serological tests {#s2b}
-----------------

HBsAg, anti-HBs, anti-HBc and anti-HCV were detected by the enzyme-linked immunosorbent assay (Kehua Bio-engineering Co., Ltd., Shanghai, China) following the manufacturer\'s instructions as described previously[@b21].

Selection and genotyping of SNPs {#s2c}
--------------------------------

We included eight key cancer-related pseudogenes from a review conducted by Poliseno et al.[@b8] ([***Supplemental Table 1***](#t06){ref-type="table"} available online). By blasting the identical sequence between pseudogenes and their parental genes, we found 31 common SNPs located in pseudogenes, with at least 50 bps flanking regions identical to their parental genes. Then, we searched miRBase (<http://www.mirbase.org/>) and Patrocles (<http://www.patrocles.org/>) to find whether the allelic change of 31 SNPs may influence miRNAs binding. Eventually, we selected six potentially functional SNPs that might affect miRNA binding (rs11682718 in *DNMT3AP1*, rs1838149 and rs9909601 in *E2F3P1*, rs2004079 in *NANOGP8*, rs9889937 in *FOXO3B*, and rs6913881 in *KRASP1*).

Genomic DNA was extracted from a leukocyte pellet by traditional proteinase K digestion, phenol-chloroform extraction and ethanol precipitation. All SNPs were genotyped using the TaqMan allelic discrimination assay on a 7900 system (Applied Biosystems, Carlsbad, CA, USA). The primers and probes for the six SNPs are shown in [***Supplemental Table 2***](#t07){ref-type="table"} (available online). Two blank (water) controls in each 384-well plate were performed for quality control, and more than 5% samples were randomly selected and repeated, yielding a 100% concordance. The success rates of genotyping for the six SNPs were all above 95%.

Statistical analysis {#s2d}
--------------------

Mean survival time was presented when the MST could not be calculated. Kaplan-Meier method and log-rank test were performed to compare the survival time in different subgroups categorized by patient characteristics, clinical features and genotypes. Univariate and multivariable Cox proportional hazard regression analyses were performed to estimate the crude or adjusted hazard ratio (HR) and their 95% confidence intervals (CI), with adjustment of age, gender, smoking status, drinking status, BCLC stage, and chemotherapy or transcatheter hepatic arterial chemoembolization (TACE) status. Cox stepwise regression model was also conducted to determine predictive factors of HCC prognosis, with a significance level of 0.050 for entering and 0.051 for removing the respective explanatory variables. The Chi-square-based *Q* test was applied to test the heterogeneity of associations between subgroups. Analyses were carried out using Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC, USA). All tests were two-sided and the criterion of statistical significance was set at *P* \< 0.05.

RESULTS {#s3}
=======

Demographic and baseline characteristics of the study subjects {#s3a}
--------------------------------------------------------------

The demographic characteristics and clinical information of the 331 HCC patients in stage B or C included in the study were described previously[@b22]. Totally, 258 of them died from HCC, and two died from other causes during up to 60.7 months of follow-up. For disease-specific survival analysis, the latter were considered as censored data in the analyses. Drinking and chemotherapy or TACE status was significantly associated with survival time (log-rank *P*  =  0.006 and \< 0.001 for drinking status and chemotherapy or TACE status, respectively). Notably, compared to those who received neither chemotherapy nor TACE therapy (MST  =  3.4 months), patients with chemotherapy or TACE therapy (MST  =  16.8 months) had a 61% significantly decreased risk of death (HR  =  0.39; 95% CI  =  0.29--0.51).

Effects of polymorphisms in pseudogenes on HCC survival {#s3b}
-------------------------------------------------------

Kaplan-Meier method and log-rank test were performed to examine the associations of the six SNPs with HCC survival in different genetic models (additive model, dominant model and recessive model). As shown in [***Table 1***](#t01){ref-type="table"}, the difference between the survival time of HCC patients and variant genotypes of rs9909601 located in *E2F3P1* was statistically significant (log-rank test: *P*  =  0.007 in the dominant model and *P*  =  0.026 in the additive model, respectively). Patients carrying rs9909601 AG/AA genotypes survived significantly longer time (MST  =  15.8 months) than those carrying rs9909601GG genotypes (MST  =  12.6 months; [***Fig. 1A***](#f01){ref-type="fig"}). Furthermore, multivariable Cox regression analysis showed that rs9909601 remained as a significant prognostic marker for HCC ([***Table 2***](#t02){ref-type="table"}). After adjusting for age, gender, smoking status, drinking status, BCLC stage, and chemotherapy or TACE status, variant genotypes of rs9909601were significantly associated with favorable prognosis of HCC (additive model: adjusted HR  =  0.69, 95% CI  =  0.56--0.86, *P*  =  0.001; dominant model: adjusted HR  =  0.56, 95% CI  =  0.43--0.73, *P* \< 0.001).

![Kaplan-Meier plots of survival by *E2F3P1* rs9909601 genotypes in the survival of hepatocellular carcinoma (HCC) patients.\
A: *E2F3P1* rs9909601 genotypes and HCC survival (log-rank *P*  =  0.007 for AG/AA vs. GG) in a dominant model. 0, patients with common genotype GG; 1, those with variant genotypes (AG/AA). B: Kaplan-Meier plots of survival by the combination of rs9909601 genotypes and chemotherapy or transcatheter hepatic arterial chemoembolization (TACE) therapy status in HCC-specific survival (log-rank *P* \< 0.001). 0, patients with variant genotypes (AG/AA) and receiving chemotherapy or TACE therapy; 1, those with common genotype (GG) and receiving chemotherapy or TACE therapy; 2, those with variant genotypes (AG/AA) and without chemotherapy and TACE therapy; 3, those with GG genotype and without chemotherapy and TACE therapy.](jbr-28-03-194-g001){#f01}

###### Genotyping results of survival of HCC patients

  SNP           Base change[a](#nt101){ref-type="table-fn"}   Pseudogene   Location   Genotyping rate   MAF[b](#nt101){ref-type="table-fn"}   Log-rank *P*          
  ------------ --------------------------------------------- ------------ ---------- ----------------- ------------------------------------- -------------- ------- -------
  rs11682718                       G\>A                       *DNMT3AP1*     2p14          99.1%                       0.110                     0.986       0.948   0.869
  rs1838149                        C\>T                        *E2F3P1*     17q12          99.7%                       0.094                     0.916       0.923   0.675
  rs9909601                        G\>A                        *E2F3P1*     17q12          97.3%                       0.362                     0.026       0.007   0.541
  rs2004079                        G\>T                       *NANOGP8*     15q14          98.2%                       0.338                     0.552       0.858   0.333
  rs9889937                        T\>C                        *FOXO3B*    17p11.2         99.1%                       0.372                     0.184       0.860   0.089
  rs6913881                        G\>A                        *KRASP1*     6p12.1         98.8%                       0.130                     0.204       0.082   0.484

HCC: hepatocellular carcinoma; SNP: single nucleotide polymorphism; MAF: minor allele frequency. ^a^major \> minor allele, ^b^MAF in patients.

###### Genotypes of *E2F3P1* rs9909601 and survival of HCC patients

  Genotype          Patients   Deaths   MST (mo)   Crude HR (95% CI)   Adjusted HR (95% CI)[a](#nt102){ref-type="table-fn"}   *P*[a](#nt102){ref-type="table-fn"}
  ---------------- ---------- -------- ---------- ------------------- ------------------------------------------------------ -------------------------------------
  rs9909601                                                                                                                  
  GG                  122       104       12.6             1                                    1                            
  AG                  167       121       16.0     0.71(0.55--0.92)                      0.54(0.41--0.71)                                   \<0.001
  AA                   33        26       15.4     0.72(0.47--1.11)                      0.67(0.43--1.05)                                    0.080
  AG/AA               200       147       15.8     0.71(0.55--0.91)                      0.56(0.43--0.73)                                   \<0.001
  Additive model                                   0.79(0.65--0.97)                      0.69(0.56--0.86)                                    0.001

HCC: hepatocellular carcinoma; MST: median survival time; HR: hazard ratio; CI: confidence intervals. ^a^Adjusted for age, gender, smoking and drinking status, BCLC stage, and chemotherapy or TACE status.

Stepwise Cox regression analysis on HCC survival {#s3c}
------------------------------------------------

Then, we performed stepwise Cox proportional hazard analysis to estimate the effects of demographic characteristics, clinical features, and *E2F3P1* rs9909601 on HCC survival. As shown in [***Table 3***](#t03){ref-type="table"}, four variables (age, drinking status, chemotherapy or TACE status, and *E2F3P1* rs9909601) were selected into the final regression model. Furthermore, when gender, smoking status and BCLC stage were included in the final model, the *E2F3P1* rs9909601 still remained as an independent protective factor for HCC survival (HR  =  0.56, 95% CI  =  0.43--0.72, *P* \< 0.001).

###### Multivariable Cox regression analysis on survival of HCC patients

  Variables                            β[a](#nt103){ref-type="table-fn"}   SE[b](#nt103){ref-type="table-fn"}    HR      95% CI       *P*
  ----------------------------------- ----------------------------------- ------------------------------------ ------ ------------ ----------
  **Stepwise regression analysis**                                                                                                 
  Chemotherapy or TACE (yes vs. no)                 −1.2569                              0.1564                 0.29   0.21--0.39   \< 0.001
  rs9909601 (AG/AA vs. GG)                          −0.5653                              0.1337                 0.57   0.44--0.74   \< 0.001
  Age (\> 53 vs. ≤ 53)                              −0.4582                              0.1366                 0.63   0.49--0.83    0.001
  Drinking status (yes *vs.* no)                    0.4124                               0.1334                 1.51   1.16--1.96    0.002
  **Final regression model**                                                                                                       
  Age (\> 53 vs. ≤53)                               −0.4714                              0.1380                 0.62   0.48--0.82    0.001
  Drinking status (yes vs. no)                      0.5495                               0.1740                 1.73   1.23--2.44    0.002
  Chemotherapy or TACE (yes vs. no)                 −1.2711                              0.1586                 0.28   0.21--0.38   \< 0.001
  rs9909601 (AG/AA vs. GG)                          −0.5880                              0.1348                 0.56   0.43--0.72   \< 0.001

HCC: hepatocellular carcinoma; HR: hazard ratio; CI: confidence intervals; TACE: transcatheter hepatic arterial chemoembolization. ^a^β is the estimated parameter of the regression model. ^b^SE is the standard error of the regression model.

Stratification and interaction analysis {#s3d}
---------------------------------------

The associations between *E2F3P1* rs9909601 and HCC survival were further investigated by stratification of age, gender, smoking status, drinking status, BCLC stage, and chemotherapy or TACE status. As shown in [***Table 4***](#t04){ref-type="table"}, we found that the protective effect of rs9909601 variant genotypes was more prominent in patients without chemotherapy and TACE (adjusted HR  =  0.45, 95% CI  =  0.28--0.73) than those with chemotherapy or TACE therapy (adjusted HR  =  0.85, 95% CI  =  0.62--1.15, *P*  =  0.029 for heterogeneity test). Therefore, a gene-chemotherapy or TACE status interaction analysis was carried out, and a statistically significant multiplicative interaction was observed (*P* for multiplicative interaction \< 0.001, [***Fig. 1B***](#f01){ref-type="fig"}). Compared to subjects with AG/AA genotypes and with chemotherapy or TACE therapy, patients with GG genotype but without chemotherapy or TACE therapy had a significantly increased mortality risk (adjusted HR  =  14.98, 95% CI  =  9.20--24.37, *P* \< 0.001) ([***Table 5***](#t05){ref-type="table"}).

###### Stratification analysis of rs9909601 genotypes associated with survival of HCC patients

  Variables                   rs9909601 (patients/deaths)   Adjusted HR (95% CI)[a](#nt104){ref-type="table-fn"}   *P* for heterogeneity  
  -------------------------- ----------------------------- ------------------------------------------------------ ----------------------- -------
  **Age, years**                                                                                                                          
  ≤53                                    61/51                                     107/83                            0.65(0.45--0.93)      0.419
  \>53                                   61/53                                     93/64                             0.52(0.35--0.78)     
  **Gender**                                                                                                                              
  Male                                  113/97                                    165/120                            0.54(0.41--0.71)      0.162
  Female                                  9/7                                      35/27                             1.06(0.43--2.62)     
  **Smoking status**                                                                                                                      
  No                                     39/32                                     76/53                             0.56(0.36--0.88)      0.718
  Yes                                    83/72                                     124/94                            0.62(0.45--0.86)     
  **Drinking status**                                                                                                                     
  No                                     46/37                                     75/52                             0.60(0.38--0.94)      0.905
  Yes                                    76/67                                     125/95                            0.58(0.42--0.81)     
  **BCLC stage**                                                                                                                          
  Stage B                               113/96                                    182/133                            0.54(0.41--0.71)      0.263
  Stage C                                 9/8                                      18/14                             0.99(0.36--2.80)     
  **Chemotherapy or TACE**                                                                                                                
  None                                   36/35                                     54/41                             0.45(0.28--0.73)      0.029
  Yes                                    86/69                                    146/106                            0.85(0.62--1.15)     

HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer stage; HR: hazard ratio; CI: confidence intervals; TACE: transcatheter hepatic arterial chemoembolization. ^a^Adjusted for age, gender, smoking and drinking status, BCLC stage, and chemotherapy or TACE status except for the stratification factor.

###### Interaction between rs9909601 genotypes and chemotherapy or TACE status

  Combined effects                      rs9909601   Chemotherapy or TACE   Patients    Deaths    MST(mo)    Crude HR (95% CI)   Adjusted HR (95% CI)[a](#nt105){ref-type="table-fn"}   *P*[a](#nt105){ref-type="table-fn"}
  ------------------------------------ ----------- ---------------------- ---------- ---------- ---------- ------------------- ------------------------------------------------------ -------------------------------------
  0                                       AG/AA             Yes              146        106        17.5             1                                    1                            
  1                                        GG               Yes               86         69        16.2     1.15(0.85--1.56)                      1.18(0.87--1.61)                                    0.290
  2                                       AG/AA             None              54         41        3.7      1.78(1.23--2.58)                      2.28(1.52--3.43)                                  \< 0.001
  3                                        GG               None              36         35        2.4      9.95(6.50--15.24)                    14.98(9.20--24.37)                                 \< 0.001
  *P* for multiplicative interaction                                                  \< 0.001   \< 0.001                                                                             

MST: median survival time; HR: hazard ratio; CI: confidence intervals; TACE: transcatheter hepatic arterial chemoembolization. ^a^Adjusted for age, gender, smoking and drinking status, BCLC stage, and chemotherapy or TACE status.

DISCUSSION {#s4}
==========

In the present study, we investigated the effects of six common SNPs in cancer-related pseudogenes on the survival of advanced HCC patients and demonstrated that *E2F3P1* rs9909601 may be an independent biomarker to predict the survival of advanced HCC patients. To the best of our knowledge, this is the first report to evaluate the role of genetic variations of pseudogene in HCC survival.

E2F was reported to regulate the expression of multiple genes that are important in cell proliferation as a transcription factor[@b25]. Specifically, it plays a critical role in the control of cell cycle[@b26],[@b27]. Recent findings suggested that the expression of *E2F3* was regulated by several miRNAs[@b28] and played a major role in modifying cellular proliferation rate which directly or indirectly affected clinical outcome of many types of tumors, including bladder cancer[@b29], prostate cancer[@b30], ovarian cancer[@b31] and breast cancer[@b32]. *E2F3P1* located in chromosome 17 is a pseudogene with sequence similar to *E2F3* in chromosome 6. Although they are in different chromosomes, *E2F3P1* may regulate *E2F3* expression by competing for miRNAs and their expressions are positively correlated[@b33]. Lees et al. have reported that genetic variations in *E2F3P1* may influence the miRNAs binding and thus may interrupt subsequent cellular activity, including proliferation and apoptosis[@b34]. Thus, it is biologically plausible that genetic variations in pseudogenes contribute to cancer risk or prognosis, given that miRNAs may provide linkage between pseudogenes and their parent genes.

By using two web-based prediction tools (miRBase and Patrocles), we found that the wild G allele of *E2F3P1* rs9909601 was more inclined to bind miR-24, miR-149, and miR-892b than the variant A allele. Both of the miR-24 and miR-149 have been investigated substantially in cancers. For instance, Han et al. identified that the overexpression of miR-24 was associated with the non-recurrence of hepatocellular carcinoma following liver transplantation which contributed to a better prognosis of HCC[@b35]. Besides, several studies have indicated that the down-regulation of miR-149 has been found in a variety of carcinomas and finally led to a worse patient survival, such as head and neck squamous cell carcinoma[@b36], colorectal cancer[@b37] and astrocytoma[@b38]. Thus, *E2F3P1* rs9909601 identified in our study may affect the impact of miRNAs regulation on gene expression by influencing the binding affinity of several special miRNAs, and hence play a role in the progression of HCC. Moreover, our analyses indicated a significant interaction between variant genotypes of rs9909601 and therapy status, which provided evidence that the effect of genetic variants on HCC prognosis could be modified by clinical factors.

In conclusion, rs9909601 at *E2F3P1* may be a useful biomarker for the prognosis of HCC survival. However, other studies with larger sample size and functional analysis are warranted to verify our finding.
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###### Information of cancer-related pseudogenes

  Genes       Corresponding pseudogenes     Location
  ---------- --------------------------- ---------------
  *KRAS*              *KRASP1*            Chr:6p12-p11
  *PTEN*              *PTENP1*              Chr:9p21
  *E2F3*              *E2F3P1*            Chr:17q11-q12
  *DNMT3A*           *DNMT3AP1*             Chr:2p14
  *FOXO3*             *FOXO3B*             Chr:17p11.2
  *NANOG*             *NANOGP8*             Chr:15q14
  *CCND3*             *CCND3P*            Chr:10p11.23
  *CDK4*              *CDK4PS*             Chr:1p21.1

###### Information of primers and probes for TaqMan allelic discrimination

  Polymorphism    Sequence(5′-3′)  
  -------------- ----------------- -----------------------------------------
  rs11682718          Primer              F: TCAAAAAGAGACAGCACCTGGAT
                                          R: GGAATTTGACCCTCTGGAAGTCTA
                       Probe         G: FAM-CTTCCTTTTCTCAGCTGGGACAG -TAMRA
                                     A: HEX-TTCCTTTTCTCAACTGGGACAGG -TAMRA
  rs1838149           Primer               F: CACCCAACCTGGTTCTCCTTT
                                            R: CCATGCTTCCATTCCCAGAA
                       Probe           C: FAM-TCAGCAAGCCCCAGGACTG -TAMRA
                                      T: HEX-TGTCAGCAAGCCTCAGGACTG -TAMRA
  rs9909601           Primer             F: CACGGTACGATAGTCTCTTGATCTG
                                            R: TCCGCTGCCTTGTTCAAAAC
                       Probe          G: FAM-AGCTCCTGAGCCAGTCACCC -TAMRA
                                      A: HEX-CAGCTCCTGAACCAGTCACCC -TAMRA
  rs2004079           Primer                F: CTTCAGGCCCACAAATCACA
                                       R: TCTTCCTCTATACTAACATGAGTGTGGAT
                       Probe         G: FAM-TTACAGTCGGATGCTTCAAAGCA -TAMRA
                                    T: HEX-TTTACAGTCGGATTCTTCAAAGCAA -TAMRA
  rs9889937           Primer               F: AGACTAGCCCGGTTCTGAAGTG
                                         R: TCCTGAAAGCAGGGTCTCAATATAA
                       Probe            T: FAM-TGCCAGAGCCTTCCGCC -TAMRA
                                        C: HEX-CCAGAGCCCTCCGCCC -TAMRA
  rs6913881           Primer        F: TCCAGTTTTCTCTGCATAAGTAATTAAAATAGACTT
                                            R: GAACTAGTTCAGGCGCCTGT
                       Probe              G: FAM-CTGGATGCAAATAA -MGB
                                       A: HEX-TTTTATCTGGATACAAATAA -MGB
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